CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- Cue Biopharma ™, Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 7, 2018-- Cue Biopharma ™, Inc., (NASDAQ: CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will be
CAMBRIDGE, Mass. , April 05, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today that it will
Dr. Suri’s appointment to senior leadership team adds depth and expertise in immunology and translational studies CAMBRIDGE, Mass. , April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics
Update on progress of selective immune modulation platform CAMBRIDGE, Mass. , May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to
Driscoll Brings More Than 20 Years of Experience in Financial Management of Life Sciences Companies CAMBRIDGE, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced progress in its ongoing
Mancilla Brings Broad Immunotherapy Business Development and Biopharmaceutical Industry Experience CAMBRIDGE, Mass. , July 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, Mass. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,